Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

@article{Connolly2018RivaroxabanWO,
  title={Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial},
  author={Stuart J. Connolly and John W. Eikelboom and Jackie Bosch and Gilles R. Dagenais and Compass investigators},
  journal={The Lancet},
  year={2018},
  volume={391},
  pages={205-218}
}
BACKGROUND Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease. METHODS In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

The coagulation system in atherothrombosis: Implications for new therapeutic strategies

Research and practice in thrombosis and haemostasis • 2018
View 9 Excerpts
Method Support
Highly Influenced